Andere Sprachen GeoVax Labs, Inc.

Aktien

A401UX

US3736786068

GOVX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 03.05.2024			% 5 Tage	% 1. Jan.
1,61 ^USD	+13,38 %		+13,38 %	-70,27 %

28.03.	GeoVax Labs, Inc. präsentiert Daten zu GEO-CM04S1, einem Covid-19-Impfstoff der nächsten Generation, auf dem World Vaccine Congress	CI
06.03.	GeoVax Labs, Inc. erreicht Meilenstein bei der Umstellung auf kommerziell validiertes Produktionssystem	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine	04.04.
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress	28.03.
GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress	28.03.
GeoVax to Present at the 36th Annual Roth Conference	12.03.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System	06.03.
GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System	06.03.
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update	29.02.
GeoVax Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024	22.02.
GeoVax to Present at the 2024 BIO CEO & Investor Conference	19.02.
GeoVax Labs Gets Two Patents from US Patent and Trademark Office	13.02.
GeoVax Announces Multiple Patent Issuances and Allowances	13.02.
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster	06.02.
Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster	06.02.
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement	29.01.
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology	08.01.
Geovax Appoints Marc Pipas as Executive Medical Director, Oncology	08.01.
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients	04.01.
GeoVax Labs, Inc. Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients	04.01.
GeoVax Announces Issuance of Malaria Vaccine Patent	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen GeoVax Labs, Inc.

Aktien

A401UX

US3736786068

GOVX

Andere Sprachen

Filter